THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 111 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $184,776 | -0.1% | 17,030 | +3.7% | 0.00% | – |
| Q4 2022 | $185,000 | +12.8% | 16,430 | +45.3% | 0.00% | – |
| Q2 2021 | $164,000 | -47.9% | 11,310 | -26.7% | 0.00% | – |
| Q1 2021 | $315,000 | -94.9% | 15,431 | -95.5% | 0.00% | -100.0% |
| Q4 2020 | $6,139,000 | -9.3% | 345,506 | -24.6% | 0.00% | -33.3% |
| Q3 2020 | $6,772,000 | -78.5% | 458,043 | -69.5% | 0.00% | -78.6% |
| Q2 2020 | $31,545,000 | -13.4% | 1,502,873 | -4.7% | 0.01% | -26.3% |
| Q1 2020 | $36,439,000 | +301.5% | 1,576,715 | +349.7% | 0.02% | +375.0% |
| Q4 2019 | $9,076,000 | +11.0% | 350,581 | -16.5% | 0.00% | 0.0% |
| Q3 2019 | $8,178,000 | +8.5% | 419,767 | -9.1% | 0.00% | +33.3% |
| Q2 2019 | $7,538,000 | +349.5% | 461,560 | +897.5% | 0.00% | +200.0% |
| Q3 2016 | $1,677,000 | +6350.0% | 46,273 | +3878.8% | 0.00% | – |
| Q3 2014 | $26,000 | -25.7% | 1,163 | +5.0% | 0.00% | – |
| Q2 2014 | $35,000 | – | 1,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |